FDA Law Blog: Biosimilars
APRIL 17, 2024
Drug Take Back Days have made appearances each spring and autumn since 2010. Events over the years have led to the removal of more than 17.9 million pounds of unwanted medication across the country. Last October’s Drug Take Back Day removed 600,000 pounds (300 tons) of medication at almost 4,700 collection sites.
National Association of Boards of Pharmacy
OCTOBER 18, 2023
Although these numbers have declined, sadly, the death toll resulting from adolescents using controlled substances has gone up. In 2021, there were 1,146 overdose deaths of adolescents in the US – more than double the number of overdose deaths in 2010 (518). of 12th graders reporting the use of narcotics other than heroin.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
National Association of Boards of Pharmacy
JANUARY 31, 2024
provided prescribers with the option to use e-prescriptions for controlled substances (CS) based on an interim final rule published in 2010. Medication errors cause avoidable harm in approximately 1 in 30 patients , with 25% of these patients experiencing severe or life-threatening harm.
FDA Law Blog: Biosimilars
APRIL 13, 2023
DEA’s bi-annual Take Back Days have collected nearly 17 million pounds of medication since 2010. DEA’s Take Back Day last October collected almost 650,000 pounds of unneeded medication at about 5,000 collection sites. More information about DEA’s National Prescription Drug Take Back Day, including disposal locations, can be found at: [link].
FDA Law Blog: Biosimilars
OCTOBER 19, 2023
DEA has held Drug Take Back Days each spring and autumn since 2010. DEA is not a band, but along with its law enforcement partners, the agency will host thousands of local drop-off locations nationwide for clearing out and proper disposal of expired and unneeded medication from medicine cabinets between 10:00 am to 2:00 p.m.
Pharmaceutical Technology
MAY 9, 2023
Xylazine started showing up in the dope in Philadelphia around 2010 and recently started to spread across the US, says Jon Zibbell, PhD, a senior public health scientist at RTI International, a non-profit research institute in North Carolina that provides data and analysis to inform public policy.”
FDA Law Blog: Biosimilars
FEBRUARY 27, 2024
2010) , however, the U.S. For several years, the PTO interpreted the term “product” to mean “active moiety” rather than “active ingredient” ( i.e. , the ion or molecule, excluding salts, esters, etc., responsible for the pharmacological action of a drug, instead of the ion or molecule including salts, esters and other derivatives).
Expert insights. Personalized for you.
59 
Let's personalize your content